18F-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and 18F-Fludeoxyglucose

摘要

Flutemetamol (¹⁸F-Flut) is an [¹⁸F]-labelled amyloid PET tracer with increasing availability. The main objectives of this study were to investigate 1) cerebrospinal fluid (CSF) Aβ 1-42 (Aβ42) concentrations associated with regional ¹⁸F-Flut uptake, 2) associations between cortical ¹⁸F-Flut and [¹⁸F]-fludeoxyglucose (¹⁸F-FDG)-PET, and 3) the potential use of ¹⁸F-Flut in WM pathology. Cognitively impaired, nondemented subjects were recruited (n = 44). CSF was drawn, and ¹⁸F-Flut-PET, ¹⁸F-FDG-PET, and MRI performed. Our main findings were: 1) Different Alzheimer’s disease predilection areas showed increased ¹⁸F-Flut retention at different CSF Aβ42 concentrations (posterior regions were involved at higher concentrations). 2) There were strong negative correlations between regional cortical ¹⁸F-Flut and ¹⁸F-FDG uptake. 3) Increased ¹⁸F-Flut uptake were observed in multiple subcortical regions in amyloid positive subjects, including investigated reference regions. However, WM hyperintensity ¹⁸F-Flut standardized uptake value ratios (SUVr) were not significantly different, thus we cannot definitely conclude that the higher uptake in ¹⁸F-Flut(+) is due to amyloid deposition. In conclusion, our findings support clinical use of CSF Aβ42, putatively relate decreasing CSF Aβ42 concentrations to a sequence of regional amyloid deposition, and associate amyloid pathology to cortical hypometabolism. However, we cannot conclude that ¹⁸F-Flut-PET is a suitable marker for WM pathology due to high aberrant WM uptake.